NASDAQ:CPRX
$15.52
(
-2.94%
)
Friday, 27th Jan 2023
Catalyst Pharmaceuticals Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $13.30 | $22.11 | Friday, 27th Jan 2023 CPRX stock ended at $15.52. This is 2.94% less than the trading day before Thursday, 26th Jan 2023. During the day the stock fluctuated 6.47% from a day low at $15.45 to a day high of $16.45. |
| 90 days | $13.30 | $22.11 | |
| 52 weeks | $5.24 | $22.11 |
Historical Catalyst Pharmaceuticals prices
| Date | Open | High | Low | Close | Volume |
| 2023-01-27 | $16.00 | $16.45 | $15.45 | $15.52 | 2 938 583 |
| 2023-01-26 | $16.98 | $16.98 | $15.87 | $15.99 | 2 905 014 |
| 2023-01-25 | $15.70 | $16.88 | $15.53 | $16.73 | 3 762 454 |
| 2023-01-24 | $14.79 | $16.25 | $14.71 | $16.12 | 5 906 344 |
| 2023-01-23 | $18.32 | $18.41 | $13.30 | $14.76 | 18 418 325 |
| 2023-01-20 | $20.45 | $21.01 | $20.31 | $20.80 | 1 915 762 |
| 2023-01-19 | $20.31 | $20.90 | $20.24 | $20.27 | 1 331 300 |
| 2023-01-18 | $20.30 | $20.69 | $19.71 | $20.43 | 2 259 002 |
| 2023-01-17 | $21.53 | $21.53 | $20.05 | $20.14 | 1 820 533 |
| 2023-01-13 | $20.83 | $22.11 | $20.75 | $21.05 | 2 756 704 |
| 2023-01-12 | $19.81 | $21.15 | $19.48 | $20.97 | 2 713 525 |
| 2023-01-11 | $19.71 | $20.60 | $19.15 | $19.81 | 2 236 249 |
| 2023-01-10 | $19.06 | $19.74 | $19.04 | $19.73 | 1 795 500 |
| 2023-01-09 | $20.20 | $20.35 | $18.92 | $19.02 | 2 859 849 |
| 2023-01-06 | $19.20 | $20.51 | $18.95 | $19.60 | 3 142 000 |
| 2023-01-05 | $18.58 | $18.98 | $18.27 | $18.83 | 1 685 896 |
| 2023-01-04 | $18.06 | $18.75 | $17.90 | $18.55 | 1 698 184 |
| 2023-01-03 | $18.70 | $18.89 | $17.94 | $18.06 | 1 898 729 |
| 2022-12-30 | $18.22 | $18.60 | $18.01 | $18.60 | 1 209 769 |
| 2022-12-29 | $18.50 | $19.00 | $18.12 | $18.34 | 1 613 070 |
| 2022-12-28 | $18.54 | $18.93 | $17.94 | $18.13 | 1 520 699 |
| 2022-12-27 | $19.04 | $19.28 | $18.47 | $18.59 | 1 633 741 |
| 2022-12-23 | $19.50 | $19.52 | $18.80 | $19.01 | 1 379 172 |
| 2022-12-22 | $19.46 | $19.70 | $18.63 | $19.35 | 2 455 266 |
| 2022-12-21 | $18.92 | $19.78 | $18.20 | $19.50 | 3 260 644 |
| 2022-12-20 | $16.80 | $18.70 | $16.76 | $18.60 | 4 076 134 |
| 2022-12-19 | $16.00 | $16.48 | $15.51 | $16.41 | 1 831 676 |
| 2022-12-16 | $16.74 | $16.96 | $15.58 | $16.00 | 4 301 155 |
| 2022-12-15 | $17.58 | $17.58 | $16.56 | $16.84 | 2 427 220 |
| 2022-12-14 | $17.78 | $18.38 | $17.65 | $17.71 | 2 344 468 |
| 2022-12-13 | $17.95 | $17.98 | $17.01 | $17.80 | 2 603 432 |
| 2022-12-12 | $16.68 | $17.66 | $16.49 | $17.41 | 2 918 602 |
| 2022-12-09 | $16.76 | $16.82 | $16.37 | $16.38 | 1 133 581 |
| 2022-12-08 | $17.01 | $17.10 | $16.62 | $16.80 | 968 962 |
| 2022-12-07 | $16.39 | $16.91 | $16.18 | $16.82 | 1 618 522 |
| 2022-12-06 | $16.95 | $17.09 | $16.19 | $16.46 | 2 296 470 |
| 2022-12-05 | $17.37 | $17.55 | $16.66 | $16.98 | 2 407 212 |
| 2022-12-02 | $16.56 | $17.55 | $16.51 | $17.27 | 3 382 384 |
| 2022-12-01 | $16.90 | $16.90 | $16.28 | $16.63 | 1 846 879 |
| 2022-11-30 | $16.61 | $16.86 | $15.95 | $16.77 | 2 990 502 |
| 2022-11-29 | $16.52 | $16.92 | $16.18 | $16.27 | 2 555 097 |
| 2022-11-28 | $17.07 | $18.39 | $16.46 | $16.49 | 3 877 527 |
| 2022-11-25 | $16.93 | $17.11 | $16.47 | $16.97 | 1 008 798 |
| 2022-11-23 | $17.45 | $17.76 | $16.76 | $17.03 | 3 807 446 |
| 2022-11-22 | $15.77 | $17.71 | $15.70 | $17.51 | 6 284 585 |
| 2022-11-21 | $15.61 | $15.68 | $14.96 | $15.55 | 1 478 916 |
| 2022-11-18 | $15.50 | $16.15 | $15.36 | $15.65 | 1 308 046 |
| 2022-11-17 | $15.03 | $15.20 | $14.75 | $15.20 | 958 321 |
| 2022-11-16 | $15.84 | $16.03 | $15.22 | $15.39 | 1 012 494 |
| 2022-11-15 | $16.00 | $16.19 | $15.47 | $15.94 | 1 564 310 |
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develop... CPRX Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
